Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
BUSINESS
Takeda Consumer Healthcare Spin-Off Now Up and Running
Takeda Consumer Healthcare, a consumer healthcare spin-off of Takeda Pharmaceutical, launched its operations on April 1, with the transfer of the drug giant’s consumer healthcare business completed the same day. The spin-off, a wholly owned subsidiary of Takeda, started out…
To read the full story
Related Article
- Takeda Consumer Healthcare President Sugimoto to Step Down following 1 Year Stint since Firm’s Inception
March 7, 2018
- Takeda Consumer Healthcare Looks to Stable, Sustainable Growth: President
June 13, 2017
- Takeda’s Consumer Healthcare Biz Split-Off Going as Scheduled
February 21, 2017
- Takeda Consumer Healthcare Unit Aims for 100 Billion Yen Sales after Spin-Off
May 31, 2016
- Takeda to Spin Off Consumer Healthcare Unit, New Firm to Go Live in April 2017
February 4, 2016
BUSINESS
- Pfizer Targets Double-Digit Oncology Growth in Japan over Next 5 Years
December 16, 2025
- Obesity Market Projected at 46.6 Billion Yen by 2040 as GLP-1s Fuel Growth: Fuji Keizai
December 15, 2025
- Roche Diagnostics Taps Ex-Medtronic Japan VP Maeda as New CEO
December 15, 2025
- RaQualia Expands Alliance with HK inno.N, Licenses Japan Rights to Reflux Therapy
December 15, 2025
- Chugai to Launch US Partnering Office in January 2026
December 15, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…